William Blair Reaffirms Outperform Rating for ARS Pharmaceuticals (NASDAQ:SPRY)

ARS Pharmaceuticals (NASDAQ:SPRY)‘s stock had its “outperform” rating reaffirmed by William Blair in a research report issued on Friday,RTT News reports.

SPRY has been the subject of a number of other reports. Leerink Partners increased their price target on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Oppenheimer assumed coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Raymond James upped their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 14th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $28.80.

ARS Pharmaceuticals Trading Down 4.6 %

Shares of ARS Pharmaceuticals stock opened at $11.24 on Friday. The stock has a 50 day moving average of $12.02 and a 200 day moving average of $13.25. ARS Pharmaceuticals has a 12 month low of $7.50 and a 12 month high of $18.51. The firm has a market cap of $1.09 billion, a PE ratio of -22.04 and a beta of 0.99.

Insider Transactions at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 14,772 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $13.75, for a total transaction of $203,115.00. Following the transaction, the director now directly owns 210,346 shares in the company, valued at $2,892,257.50. This trade represents a 6.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Brian Dorsey sold 25,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $12.30, for a total value of $307,500.00. Following the transaction, the chief operating officer now owns 6,024 shares in the company, valued at $74,095.20. The trade was a 80.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 617,102 shares of company stock worth $7,935,840. 40.10% of the stock is currently owned by company insiders.

Institutional Trading of ARS Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of SPRY. Creative Planning boosted its position in ARS Pharmaceuticals by 7.0% during the 3rd quarter. Creative Planning now owns 35,263 shares of the company’s stock valued at $511,000 after acquiring an additional 2,307 shares in the last quarter. Raymond James & Associates bought a new stake in ARS Pharmaceuticals during the 3rd quarter valued at $2,969,000. Allspring Global Investments Holdings LLC bought a new stake in ARS Pharmaceuticals during the 3rd quarter valued at $2,584,000. Wealth Enhancement Advisory Services LLC boosted its position in ARS Pharmaceuticals by 9.1% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 57,624 shares of the company’s stock valued at $836,000 after acquiring an additional 4,810 shares in the last quarter. Finally, J.W. Cole Advisors Inc. boosted its position in ARS Pharmaceuticals by 33.2% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 20,520 shares of the company’s stock valued at $298,000 after acquiring an additional 5,120 shares in the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.